EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access

Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR - or ALK -Rearranged or Translocated Non–Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)

Phase-III-randomisierte Studie von Atezolizumab plus Bevacizumab und Chemotherapie bei Patient:innen mit EGFR- oder ALK-rearrangiertem bzw. translokiertem nichtkleinzelligem Lungenkarzinom (ATTLAS, KCSG-LU19-04)

Sehhoon Park iD, Tae Min Kim iD, Ji-Youn Han iD, Gyeong-Won Lee iD, Byoung Yong Shim iD, Yun-Gyoo Lee iD, Sang-We Kim, Il Hwan Kim, Suee Lee, Yu Jung Kim iD, Ji Hyun Park, Sang-Gon Park und 12 weitere

Journal of Clinical Oncology · 10.04.2024 · 42 (11) · 1241-1251

DOI: 10.1200/jco.23.01891 ↗

Auf einen Blick

Bei NSCLC nach TKI-Versagen verbesserte ABCP das progressionsfreie Überleben gegenüber PC. Das Gesamtüberleben war ähnlich; Nebenwirkungen traten unter ABCP häufiger auf.

Fragestellung

Verbessert Atezolizumab plus Bevacizumab und Chemotherapie bei EGFR- oder ALK-verändertem NSCLC nach Progress unter TKI die Wirksamkeit gegenüber Pemetrexed plus Platinchemotherapie?

Methode

Randomisierte, offene, multizentrische Phase-III-Studie in 16 Zentren in Korea; Vergleich von ABCP mit anschließender Erhaltungstherapie gegen PC mit Pemetrexed-Erhaltung.

Ergebnisse

228 Patient:innen: 154 im ABCP- und 74 im PC-Arm. ORR 69,5 % vs. 41,9 % (P < .001); medianes PFS 8,48 vs. 5,62 Monate; HR 0,62 (95 %-KI 0,45–0,86; P = .004). OS 20,63 vs. 20,27 Monate; HR 1,01 (95 %-KI 0,69–1,46; P = .975).

Einschränkungen

Höhere Raten behandlungsbedingter unerwünschter Ereignisse unter ABCP als unter PC.

Schlussfolgerung der Autor:innen

Dies ist nach Angaben der Autor:innen die erste randomisierte Phase-III-Studie, die einen klinischen Nutzen einer anti-PD-L1-Antikörper-Kombination mit Bevacizumab und Chemotherapie bei dieser Patient:innengruppe zeigt.

Kernaussagen

  • ABCP verbesserte das PFS gegenüber PC
  • ORR unter ABCP höher: 69,5 % vs. 41,9 %
  • Kein Unterschied im Gesamtüberleben

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.04.2024. Verfasst von Sehhoon Park und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 181-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE In the treatment of non–small-cell lung cancer (NSCLC) with a driver mutation, the role of anti–PD-(L)1 antibody after tyrosine kinase inhibitor (TKI) remains unclear. This randomized, open-label, multicenter, phase III study evaluates the efficacy of atezolizumab plus bevacizumab, paclitaxel, and carboplatin (ABCP ) in EGFR- or ALK-rearranged or translocated NSCLC upon progression on TKI therapy. MATERIALS AND METHODS We compared the clinical efficacy of ABCP followed by maintenance therapy with atezolizumab plus bevacizumab with pemetrexed plus carboplatin or cisplatin (PC) followed by pemetrexed maintenance. The primary end point was progression-free survival (PFS). RESULTS A total of 228 patients with activating EGFR mutation (n = 215) or ALK translocation (n = 13) were enrolled from 16 sites in the Republic of Korea and randomly assigned at 2:1 ratio to either ABCP (n = 154) or PC arm (n = 74). The median follow-up duration was 26.1 months (95% CI, 24.7 to 28.2). Objective response rates (69.5% v 41.9%, P < .001) and median PFS (8.48 v 5.62 months, hazard ratio [HR], 0.62 [95% CI, 0.45 to 0.86]; P = .004) were significantly better in the ABCP than PC arm. PFS benefit increased as PD-L1 expression increased, with an HR of 0.47, 0.41, and 0.24 for PD-L1 ≥1%, ≥10%, and ≥50%, respectively. Overall survival was similar between ABCP and PC arm (20.63 v 20.27 months, HR, 1.01 [95% CI, 0.69 to 1.46]; P = .975). The safety profile of the ABCP arm was comparable with that previously reported, with no additional safety signals, but higher rates of treatment-related adverse events were observed compared with the PC arm. CONCLUSION To our knowledge, this study is the first randomized phase III study to demonstrate the clinical benefit of anti–PD-L1 antibody in combination with bevacizumab and chemotherapy in patients with EGFR- or ALK-rearranged or translocated NSCLC who have progressed on relevant targeted therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntibodies, Monoclonal, HumanizedHumansBevacizumabCarboplatinB7-H1 AntigenPemetrexedErbB ReceptorsReceptor Protein-Tyrosine KinasesAntineoplastic Combined Chemotherapy Protocols

Substanzen

atezolizumabBevacizumabCarboplatinB7-H1 AntigenPemetrexedErbB ReceptorsReceptor Protein-Tyrosine KinasesEGFR protein, humanAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Seoul National University Hospital, Seoul National University Cancer Research Institute, Seoul, Korea.
  • Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang-si Gyeonggi-do, Korea.
  • Divisions of Hematology and Oncology, Department of Internal Medicine, Institute of Health Science, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea.
  • Division of Medical Oncology, Department of Internal Medicine, St Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Division of Hematology & Medical Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.

ORCID-Profile: Sehhoon Park, Tae Min Kim, Ji-Youn Han, Gyeong-Won Lee, Byoung Yong Shim, Yun-Gyoo Lee, Yu Jung Kim, Ki Hyeong Lee, Eun Joo Kang, Ju Won Kim, Seong-Hoon Shin, Chan-Young Ock, Hyun-Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn

Zitieren

APA

Park, S., Kim, T. M., Han, J. Y., Lee, G. W., Shim, B. Y., Lee, Y. G., Kim, S. W., Kim, I. H., Lee, S., Kim, Y. J., Park, J. H., Park, S. G., Lee, K. H., Kang, E. J., Kim, J. W., Shin, S. H., Ock, C. Y., Nam, B. H., Lee, J., …, & Ahn, M. J. (2024). Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR - or ALK -Rearranged or Translocated Non–Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04). Journal of Clinical Oncology, 42(11), 1241-1251. https://doi.org/10.1200/jco.23.01891

Vancouver

Park S, Kim TM, Han JY, Lee GW, Shim BY, Lee YG, et al. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR - or ALK -Rearranged or Translocated Non–Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04). Journal of Clinical Oncology. 2024;42(11):1241-1251. doi:10.1200/jco.23.01891

BibTeX
@article{Park2024,
  author = {Park, Sehhoon and Kim, Tae Min and Han, Ji-Youn and Lee, Gyeong-Won and Shim, Byoung Yong and Lee, Yun-Gyoo and Kim, Sang-We and Kim, Il Hwan and Lee, Suee and Kim, Yu Jung and Park, Ji Hyun and Park, Sang-Gon and Lee, Ki Hyeong and Kang, Eun Joo and Kim, Ju Won and Shin, Seong-Hoon and Ock, Chan-Young and Nam, Byung-Ho and Lee, Jaebong and Jung, Hyun-Ae and Sun, Jong-Mu and Lee, Se-Hoon and Ahn, Jin Seok and Ahn, Myung-Ju},
  title = {Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR - or ALK -Rearranged or Translocated Non–Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {11},
  pages = {1241--1251},
  doi = {10.1200/jco.23.01891}
}
Kostenlos starten →